The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade after Passage of the Prescription Drug User Fee Act of 1992

Drug Information Journal

Volumn 37, Issue 4, 2003, Pages 357-371

  Kaitin, Kenneth I ^a   Cairns, Catherine ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug development; FDA Modernization Act of 1997; Food and Drug Administration; New chemical entity; Pharmaceutical industry; Pharmaceutical innovation; Prescription Drug User Fee Act of 1992

Indexed keywords

ALITRETINOIN; AMINOLEVULINIC ACID; AMPRENAVIR; BEXAROTENE; CILOSTAZOL; DALFOPRISTIN PLUS QUINUPRISTIN; DEXMEDETOMIDINE; DOFETILIDE; DOXERCALCIFEROL; ENTACAPONE; EPIRUBICIN; ETIRACETAM; EXEMESTANE; FERRIC GLUCONATE; GANIRELIX; GATIFLOXACIN; KETOTIFEN FUMARATE; MEQUINOL PLUS RETINOIC ACID; MOXIFLOXACIN; NEW DRUG; NITRIC OXIDE; OSELTAMIVIR; PEMIROLAST; PIOGLITAZONE; PORACTANT; RAPAMYCIN; ROFECOXIB; ROSIGLITAZONE; TEMOZOLOMIDE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; ZANAMIVIR;

DRUG APPROVAL; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0345257875     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150303700403     Document Type: Review

References (18)

1. Prescription Drug User Fee Act of 1992. Public Law 102-571 (1992);21 USC 379;106 Stat 4491.
2. Food and Drug Administration Modernization Act of 1997. Pub Law 105-115 (1997 Nov 21); 21 U.S.C. 355a; 111 Stat 2296.
3. Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Inf J. 2000;34(1)1-14.
4. Kaitin KI, Manocchia MA. The new drug approvals of 1995, 1994, and 1995: trends in drug development. Am J Ther. 1997;4(1):46-54.
5. Kaitin KI, Manocchia M, Seijbring M, Lasagna L. The new drug approvals of 1990, 1991, and 1992: trends in drug development. J Clin Pharmacol. 1994;34(2):120-127.
6. Kaitin KI, DiCerbo PA, Lasagna L. The new drug approvals of 1987, 1988, and 1989: trends in drug development. J Clin Pharmacol. 1991;31(2):116-122.
7. Kaitin KI, Richard BW, Lasagna L. Trends in drug development: the 1985-86 new drug approvals. J Clin Pharmacol. 1987;27(8):542-548.
8. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;Mar;22(2):151-185.
9. Pfizer sees R&D rebound, says FDA safety reviews "not inappropriate." Pink Sheet. 2002;64(38):15-16.
10. FDA sees drug discovery technology, mergers cutting down on NDAs. Pink Sheet. 2003;65(10):27.
11. U.S. Food and Drug Administration. Improving innovation in medical technology: beyond 2002. http://www.fda.gov/bbs/topics/NEWS//2003/beyond2002/report.html (Accessed January 31, 2002).
12. DiMasi JA. New drug development in the United States 1963-1999. Clin Pharmacol Ther. 2001;69(5):286-296.
13. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. PharmacoEcon. 2002;20 (Suppl 3):1-10.
14. "Sensible regulation" will maintain U.S. lead in Rx launches, FDA says. Pink Sheet. 2003;65(19):24.
15. US Food and Drug Administration. Center for Drug Evaluation and Research 2002 report to the nation: Improving public health through human drugs. http://www.fda.gov/cder/reports/rtn/2002/rtn2002.pdf (Accessed May 15, 2003).
16. Reichert JM, Milne C-P. Public and private sector contributions to the discovery and development of 'impact' drugs. Am J Ther. 2002;9(12):543-555.
17. All ethical pharmaceuticals. Medical & Healthcare Marketplace Guide. 18th edition. Smith RC, editor. Philadelphia, PA: Dorland, 2003:I-83-85.
18. Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Public Law 107-116; 116 Stat 594 (Title V, Subtitle, A Prescription Drug User Fees, Sec 501-509).